Originally posted March 2018

Chad Gibson wraps up Neurotech Reports’ Bioelectronic Medicine with what could be the most important message of the day ‘regulatory and reimbursement [strategies] are just as critical as the technical feasibility, and go-to-market strategy should consider these aspects.’  Amen to that!

Agenda